{"transactions":[{"id":1186460,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-01T18:08:53.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Due to the Reporting Person's termination of employment, the unvested Stock Option was forfeited."}],"balance_after":1875,"derivative":{"exercise_price":1.2,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001104659-25-030688","document":"tm2511097-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465925030688/tm2511097-7_4seq1.xml","form_type":"4"}},{"id":1328699,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T18:10:14.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":2606,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-129464","document":"tm2431371-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924129464/tm2431371-5_4seq1.xml","form_type":"4"}},{"id":1328698,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-17T18:10:14.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":165,"price":0.3523,"value":58.1295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023."}],"balance_after":19957,"source":{"system":"sec-edgar","filing":"0001104659-24-129464","document":"tm2431371-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924129464/tm2431371-5_4seq1.xml","form_type":"4"}},{"id":1328697,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-17T18:10:14.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20122,"source":{"system":"sec-edgar","filing":"0001104659-24-129464","document":"tm2431371-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924129464/tm2431371-5_4seq1.xml","form_type":"4"}},{"id":1392044,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-03T21:53:54.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":5556,"price":0.55,"value":3055.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5501. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":19601,"source":{"system":"sec-edgar","filing":"0001104659-24-106060","document":"tm2425607-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924106060/tm2425607-1_4seq1.xml","form_type":"4"}},{"id":1392043,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-03T21:53:54.000Z","date":"2024-09-17","kind":"grant","planned":true,"acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the \"PSUs\"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024."}],"balance_after":25157,"source":{"system":"sec-edgar","filing":"0001104659-24-106060","document":"tm2425607-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924106060/tm2425607-1_4seq1.xml","form_type":"4"}},{"id":1405097,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T19:19:17.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":3127,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-100747","document":"tm2424255-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924100747/tm2424255-1_4seq1.xml","form_type":"4"}},{"id":1405096,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-09-17T19:19:17.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":138,"price":0.6908,"value":95.3304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023."}],"balance_after":3907,"source":{"system":"sec-edgar","filing":"0001104659-24-100747","document":"tm2424255-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924100747/tm2424255-1_4seq1.xml","form_type":"4"}},{"id":1405095,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-09-17T19:19:17.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4045,"source":{"system":"sec-edgar","filing":"0001104659-24-100747","document":"tm2424255-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924100747/tm2424255-1_4seq1.xml","form_type":"4"}},{"id":1475356,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-06-18T21:25:11.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":3648,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-073000","document":"tm2417544-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924073000/tm2417544-2_4seq1.xml","form_type":"4"}},{"id":1475355,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-06-18T21:25:11.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":155,"price":1.285,"value":199.175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023."}],"balance_after":3524,"source":{"system":"sec-edgar","filing":"0001104659-24-073000","document":"tm2417544-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924073000/tm2417544-2_4seq1.xml","form_type":"4"}},{"id":1475354,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-06-18T21:25:11.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3679,"source":{"system":"sec-edgar","filing":"0001104659-24-073000","document":"tm2417544-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924073000/tm2417544-2_4seq1.xml","form_type":"4"}},{"id":1545666,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T19:32:58.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6750,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001104659-24-044862","document":"tm2411220-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924044862/tm2411220-6_4seq1.xml","form_type":"4"}},{"id":1545665,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T19:32:58.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":4169,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-044862","document":"tm2411220-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924044862/tm2411220-6_4seq1.xml","form_type":"4"}},{"id":1545664,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-08T19:32:58.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":165,"price":2.6211,"value":432.4815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023."}],"balance_after":5408,"source":{"system":"sec-edgar","filing":"0001104659-24-044862","document":"tm2411220-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924044862/tm2411220-6_4seq1.xml","form_type":"4"}},{"id":1545663,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-08T19:32:58.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":5573,"source":{"system":"sec-edgar","filing":"0001104659-24-044862","document":"tm2411220-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924044862/tm2411220-6_4seq1.xml","form_type":"4"}},{"id":1545662,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-08T19:32:58.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3323,"source":{"system":"sec-edgar","filing":"0001104659-24-044862","document":"tm2411220-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465924044862/tm2411220-6_4seq1.xml","form_type":"4"}},{"id":1707239,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-18T16:47:32.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":4690,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-126916","document":"tm2333119-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923126916/tm2333119-1_4seq1.xml","form_type":"4"}},{"id":1707238,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-18T16:47:32.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":2802,"source":{"system":"sec-edgar","filing":"0001104659-23-126916","document":"tm2333119-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923126916/tm2333119-1_4seq1.xml","form_type":"4"}},{"id":1778927,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-18T16:47:38.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5211,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-101637","document":"tm2326350-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923101637/tm2326350-4_4seq1.xml","form_type":"4"}},{"id":1778926,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-18T16:47:38.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":2281,"source":{"system":"sec-edgar","filing":"0001104659-23-101637","document":"tm2326350-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923101637/tm2326350-4_4seq1.xml","form_type":"4"}},{"id":1852257,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-16T18:36:37.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5732,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-072395","document":"tm2319006-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923072395/tm2319006-1_4seq1.xml","form_type":"4"}},{"id":1852256,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-06-16T18:36:37.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1760,"source":{"system":"sec-edgar","filing":"0001104659-23-072395","document":"tm2319006-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923072395/tm2319006-1_4seq1.xml","form_type":"4"}},{"id":1950063,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T17:59:44.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":32000,"derivative":{"exercise_price":19.6,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-23-033402","document":"tm239796-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923033402/tm239796-3_4seq1.xml","form_type":"4"}},{"id":1950062,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T17:59:44.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-23-033402","document":"tm239796-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923033402/tm239796-3_4seq1.xml","form_type":"4"}},{"id":1950061,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T17:59:44.000Z","date":"2023-03-14","kind":"exercise","acquired":false,"shares":2084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6253,"derivative":{"underlying":"Common Stock","underlying_shares":2084},"source":{"system":"sec-edgar","filing":"0001104659-23-033402","document":"tm239796-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923033402/tm239796-3_4seq1.xml","form_type":"4"}},{"id":1950060,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-16T17:59:44.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":845,"price":19.695,"value":16642.275,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022."}],"balance_after":1239,"source":{"system":"sec-edgar","filing":"0001104659-23-033402","document":"tm239796-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923033402/tm239796-3_4seq1.xml","form_type":"4"}},{"id":1950059,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-16T17:59:44.000Z","date":"2023-03-14","kind":"exercise","acquired":true,"shares":2084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":2084,"source":{"system":"sec-edgar","filing":"0001104659-23-033402","document":"tm239796-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923033402/tm239796-3_4seq1.xml","form_type":"4"}},{"id":2047502,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-24T20:04:38.000Z","date":"2023-01-20","kind":"exercise","acquired":false,"shares":29713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are fully vested and exercisable."}],"balance_after":29712,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":29713},"source":{"system":"sec-edgar","filing":"0001104659-23-006295","document":"tm232491-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923006295/tm232491-2_4seq1.xml","form_type":"4"}},{"id":2047501,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-24T20:04:38.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":29713,"price":30,"value":891390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $30.00 to $30.05. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-006295","document":"tm232491-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923006295/tm232491-2_4seq1.xml","form_type":"4"}},{"id":2047500,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-24T20:04:38.000Z","date":"2023-01-20","kind":"exercise","acquired":true,"shares":29713,"price":0.41,"value":12182.33,"ownership":{"direct":true},"balance_after":29713,"source":{"system":"sec-edgar","filing":"0001104659-23-006295","document":"tm232491-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465923006295/tm232491-2_4seq1.xml","form_type":"4"}},{"id":2330774,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-16T16:20:18.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":8337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":8337,"derivative":{"underlying":"Common Stock","underlying_shares":8337},"source":{"system":"sec-edgar","filing":"0001104659-22-034508","document":"tm229449-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465922034508/tm229449-5_4seq1.xml","form_type":"4"}},{"id":2769327,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-29T20:53:03.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 25, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":41.17,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-043488","document":"tm217124-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921043488/tm217124-14_4seq1.xml","form_type":"4"}},{"id":2846296,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option has vested or will vest as to the original 31,047 underlying shares in substantially equal monthly installments over the 48 months that began on April 12, 2018, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"In the Form 4 reporting the grant of this option award, dated March 13, 2018, the total number of derivative securities beneficially owned was shown as 155,472. The correct number should have been 31,047."}],"balance_after":21047,"derivative":{"exercise_price":11,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846295,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested and became exercisable as to 25% of the original 124,425 underlying shares on August 22, 2018, and the remaining 75% of underlying shares have vested or will vest in substantially equal monthly installments over the 36 months thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":59425,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846294,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":600,"price":57.17,"value":34302.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.03 to $57.25. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846293,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":9573,"price":56.6,"value":541831.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.03 to $56.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":600,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846292,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":6872,"price":55.55,"value":381739.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10173,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846291,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":5655,"price":54.45,"value":307914.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.09 to $54.88. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17045,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846290,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":2300,"price":53.77,"value":123671.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $53.89. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":22700,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846289,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":10000,"price":11,"value":110000.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2846288,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-19T19:35:38.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":15000,"price":0.41,"value":6150.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001104659-21-025878","document":"tm217124-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921025878/tm217124-2_4seq1.xml","form_type":"4"}},{"id":2900810,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested and became exercisable as to 25% of the original 124,425 underlying shares on August 22, 2018, and the remaining 75% of underlying shares have vested or will vest in substantially equal monthly installments over the 36 months thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":74425,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2900809,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":1377,"price":52.45,"value":72223.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.52. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2900808,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":1500,"price":51.45,"value":77175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.83. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1377,"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2900807,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":2700,"price":50.38,"value":136026.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2877,"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2900806,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":12665,"price":49.27,"value":624004.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5577,"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2900805,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":6758,"price":48.43,"value":327289.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.02 to $48.99. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18242,"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2900804,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-21T16:15:34.000Z","date":"2021-01-19","kind":"exercise","acquired":true,"shares":25000,"price":0.41,"value":10250.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-21-006311","document":"tm213770-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465921006311/tm213770-1_4seq1.xml","form_type":"4"}},{"id":2928853,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-12-30T16:15:36.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested and became exercisable as to 25% of the original 124,425 underlying shares on August 22, 2018, and the remaining 75% of underlying shares have vested or will vest in substantially equal monthly installments over the 36 months thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Reporting Person's Form 3, filed March 7, 2018, inadvertently reported that the expiration date was March 23, 2027."}],"balance_after":99425,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-20-140550","document":"tm2039560-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920140550/tm2039560-1_4seq1.xml","form_type":"4"}},{"id":2928852,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-30T16:15:36.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":1353,"price":53.54,"value":72439.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.49 to $53.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-140550","document":"tm2039560-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920140550/tm2039560-1_4seq1.xml","form_type":"4"}},{"id":2928851,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-30T16:15:36.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":3951,"price":52.68,"value":208138.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.46 to $52.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1353,"source":{"system":"sec-edgar","filing":"0001104659-20-140550","document":"tm2039560-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920140550/tm2039560-1_4seq1.xml","form_type":"4"}},{"id":2928850,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-30T16:15:36.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":5727,"price":51.75,"value":296372.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.37 to $52.35. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5304,"source":{"system":"sec-edgar","filing":"0001104659-20-140550","document":"tm2039560-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920140550/tm2039560-1_4seq1.xml","form_type":"4"}},{"id":2928849,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-30T16:15:36.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":13969,"price":50.77,"value":709206.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.37 to $51.36. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":11031,"source":{"system":"sec-edgar","filing":"0001104659-20-140550","document":"tm2039560-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920140550/tm2039560-1_4seq1.xml","form_type":"4"}},{"id":2928848,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-30T16:15:36.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":25000,"price":0.41,"value":10250.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-20-140550","document":"tm2039560-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920140550/tm2039560-1_4seq1.xml","form_type":"4"}},{"id":3132285,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-28T16:15:31.000Z","date":"2020-05-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of May 26, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":40000,"derivative":{"exercise_price":45.99,"expiration_date":"2030-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-067050","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465920067050/a4.xml","form_type":"4"}},{"id":3998476,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":81360,"kind":"person","name":"O'Neill Vincent","position":1,"cik":"0001672718","reported_name":"O'Neill Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options","published_at":"2018-03-13T17:10:25.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":31047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest as follows: in equal monthly installments over the 48 months following the date of grant, begininning on 4/12/2018."}],"balance_after":155472,"derivative":{"exercise_price":11,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":31047},"source":{"system":"sec-edgar","filing":"0001104659-18-017146","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672718/000110465918017146/a4.xml","form_type":"4"}}]}